Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

Albert Einstein College of Medicine

Status and phase

Completed

Phase 2

Conditions

Type 2 Diabetes Mellitus

Insulin Resistance

Treatments

Drug: Resveratrol

Study type

Interventional

Funder types

Other

Identifiers

NCT01354977

2007-534

Details and patient eligibility

About

Resveratrol is a natural polyphenol (a compound containing a phenol functional group) that can be found in many plants. The purpose of this research is to study the effects of resveratrol on the action of insulin (a hormone produced in the body by the pancreas that regulates the amount of sugar in the blood), fat accumulation, and inflammation in the body.

Full description

Participants will meet with the study team to discuss dietary recommendations. Each participant will be instructed to follow a standardized diet plan and to avoid vigorous exercise before beginning the study. Participants will be given a 28 day supply of resveratrol capsules (Two 500 mg capsules taken twice a day). A comprehensive study of whole-body insulin action called a pancreatic clamp will be done and small samples of fat and muscle will be taken before and after the administration of resveratrol.

Enrollment

20 patients

Sex

All

Ages

45 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

BMI: 26-35
Non-smoker
Normal screening labs (CMC, chemistry, LFTs PT/PTT)
No CAD
Good IV access

Exclusion criteria

High cholesterol
<4 week history of participation in another drug trial
Severe hypertension
Heart disease
Liver disease of liver abnormalities
Cerebrovascular disease, i.e. stroke
CVD
Seizures
Bleeding disorders
Muscle disease
Cancer
HIV
Hepatitis (all types)
Mentally disabled persons
Pregnant women
Allergies to Novocaine, Lidocaine, Benzocaine
Subjects on the following medications:
- Anticoagulant and antiplatelet drugs
- Anti-epileptic drugs
- Mexiletene
- Quinidine
- Cyclosporine
- Tacrolimus
- HIV protease inhibitors